Health and Fitness Health and Fitness
Fri, June 18, 2010
Thu, June 17, 2010
Wed, June 16, 2010
Tue, June 15, 2010
Mon, June 14, 2010
Sat, June 12, 2010
Fri, June 11, 2010
Thu, June 10, 2010
Wed, June 9, 2010
Tue, June 8, 2010
[ Tue, Jun 08th 2010 ] - Market Wire
O.C. Beverages Products Arrive
Mon, June 7, 2010
Sun, June 6, 2010
Sat, June 5, 2010
Fri, June 4, 2010
Thu, June 3, 2010
Wed, June 2, 2010

NPS Pharmaceuticals to Present at ThinkEquity Healthcare Conference


//health-fitness.news-articles.net/content/2010/ .. resent-at-thinkequity-healthcare-conference.html
Published in Health and Fitness on Thursday, June 10th 2010 at 13:15 GMT by Market Wire   Print publication without navigation


BEDMINSTER, N.J.--([ BUSINESS WIRE ])--NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that Francois Nader, M.D., president and chief executive officer, is scheduled to present at the ThinkEquity Mid Year Check-Up on Healthcare Conference in New York on Wednesday, June 16, 2010 at 2:00 p.m. ET. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. Interested parties may access the webcast from the investorsa™ calendar of events page on the NPS website at [ http://www.npsp.com ].

About NPS Pharmaceuticals

NPS Pharmaceuticals is developing new treatment options for patients with rare gastrointestinal and endocrine disorders. The company is currently advancing two Phase 3 registration programs. Teduglutide, a proprietary analog of GLP-2, is being evaluated as GATTEX® in a Phase 3 registration study known as STEPS for intestinal failure associated with short bowel syndrome and is in preclinical development for chemotherapy-induced gastrointestinal mucositis and other pediatric indications. NPSP558 (recombinant parathyroid hormone 1-84 [rDNA origin] injection) is being evaluated in a Phase 3 registration study known as REPLACE as a hormone replacement therapy for hypoparathyroidism. NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, Kyowa Hakko Kirin, Nycomed, and Ortho-McNeil Pharmaceutical. Additional information is available at [ http://www.npsp.com ].


Publication Contributing Sources